CalciMedica Announces Upcoming Symposium at the 43rd Vicenza Course AKI-CRRT-EBPT and Critical Care Nephrology Meeting

Rhea-AI Summary

CalciMedica announced an upcoming symposium titled 'Auxora for the Treatment of AKI' at the 43rd Vicenza Course AKI-CRRT-EBPT and Critical Care Nephrology meeting in Vicenza, Italy from June 24-26. The symposium will feature three presentations: Dr. Sudarshan Hebbar will discuss CRAC Channels, Dr. Javier Neyra will present on IL-17's role in AKI pathophysiology, and Dr. Lakhmir Chawla will cover the KOURAGE study. The presentations will be available as webcasts on CalciMedica's IR website after the sessions. The company focuses on developing CRAC channel inhibition therapies for inflammatory and immunologic illnesses.

LA JOLLA, Calif., June 12, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced an upcoming symposium entitled "Auxora for the Treatment of AKI" at the 43rd Vicenza Course AKI-CRRT-EBPT and Critical Care Nephrology meeting being held June 24-26 in Vicenza, Italy.

Details for the oral presentations to be presented during the symposium are as follows:

Presentation Title: Overview of Calcium Release-Activated Calcium (CRAC) Channels
Presenter: Sudarshan Hebbar, M.D., Chief Medical Officer of CalciMedica
Date and Time: Tuesday, June 24, 1:45-2:00 p.m. CEST

Presentation Title: The Role of IL-17 in the Pathophysiology of AKI
Presenter: Javier Neyra, M.D., Associate Professor of Medicine and Associate Director of the Nephrology Research & Training Center at University of Alabama at Birmingham
Date and Time: Tuesday, June 24, 2:00-2:20 p.m. CEST

Presentation Title: KOURAGE (NCT06374797)
Presenter: Lakhmir Chawla, M.D., Clinical Professor of Medicine at University of California San Diego, Chief Medical Officer at ExThera Medical, and Chair of the KOURAGE Steering Committee
Date and Time: Tuesday, June 24, 2:20-2:35 p.m. CEST

Webcasts of the presentations will be available following the sessions on the Medical Events & Presentations section of CalciMedica's IR website at https://ir.calcimedica.com/news-events/medical-events-publications.

About CalciMedica
CalciMedica is a clinical-stage biopharmaceutical company focused on developing novel CRAC channel inhibition therapies for inflammatory and immunologic diseases. CalciMedica's proprietary technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory and immunologic diseases for which there are currently no approved therapies. CalciMedica's lead product candidate Auxora™ has demonstrated positive and consistent clinical results in multiple completed efficacy clinical trials and been well-tolerated in over 350 critically ill patients dosed. CalciMedica has announced data for a Phase 2b trial (called CARPO – NCT04681066) in patients with acute pancreatitis (AP) and accompanying systemic inflammatory response syndrome (SIRS) and for a Phase 2 trial (called CARDEA – NCT04345614) in patients with COVID pneumonia. The Company is currently conducting a Phase 2 trial (called KOURAGE –NCT06374797) in patients with acute kidney injury (AKI) with associated acute hypoxemic respiratory failure (AHRF). For more information, please visit www.calcimedica.com.

Contact Information
Argot Partners
calcimedica@argotpartners.com
(212) 600-1902

View original content to download multimedia:https://www.prnewswire.com/news-releases/calcimedica-announces-upcoming-symposium-at-the-43rd-vicenza-course-aki-crrt-ebpt-and-critical-care-nephrology-meeting-302479338.html

SOURCE CalciMedica, Inc.

FAQ

When and where is CalciMedica (CALC) presenting at the Vicenza Course meeting?

CalciMedica is presenting on Tuesday, June 24, 2025, between 1:45-2:35 p.m. CEST at the 43rd Vicenza Course in Vicenza, Italy.

What topics will be covered in CalciMedica's (CALC) symposium presentations?

The symposium will cover CRAC Channels overview, IL-17's role in AKI pathophysiology, and the KOURAGE study (NCT06374797).

Who are the presenters at CalciMedica's (CALC) AKI symposium?

The presenters are Dr. Sudarshan Hebbar (CalciMedica CMO), Dr. Javier Neyra (University of Alabama), and Dr. Lakhmir Chawla (UC San Diego).

Where can I watch CalciMedica's (CALC) symposium presentations?

Webcasts will be available after the sessions on CalciMedica's IR website at ir.calcimedica.com in the Medical Events & Presentations section.

What is CalciMedica's (CALC) main therapeutic focus?

CalciMedica focuses on developing CRAC channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses.